As a result, estimated annual spending on GLP-1 drugs among non-diabetics rose from $1.6 billion between 2018 and 2021 to $5.8 billion in 2022, the study showed.

As a result, estimated annual spending on GLP-1 drugs among non-diabetics rose from $1.6 billion between 2018 and 2021 to $5.8 billion in 2022, the study showed.

A separate Prime analysis, however, of year-over-year claims data for Wegovy and Zepbound only found an improvement in ...

In a trial, the daily GLP-1 pill showed "significant" results and similar side effects to injectable GLP-1 drugs like Ozempic ...

When researchers analyzed weight loss results from patients who took GLP-1 drugs and those who'd undergone bariatric surgery, ...

Of the 102,166 GLP-1s analyzed, 94% had some form of commercial insurance, yet cost-saving options were still widely overlooked.

The rising use of glucagon-like peptide-1 (GLP-1) receptor agonists for weight loss is changing how Americans eat, with implications already visible in the food and beverage industry. A new study from ...

People taking GLP-1 drugs can decrease fat mass while minimizing muscle loss with a few key strategies that include proper supervision, and a protein-rich diet, the results of a new study suggest.

In a matched group of more than 170,000 adults, those treated with GLP-1 agonists had a lower risk of developing an obesity-related cancer over a median follow-up of about 4 years when compared ...

The rising use of glucagon-like peptide-1 (GLP-1) receptor agonists for weight loss is changing how Americans eat, with implications already visible in the food and beverage industry. A new study from ...